Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Irene Litvan

Showing results (321-330 of 331) with videos related to

Pageof 34
Sort By:
Nature Aging|May 16, 2025
Large-scale network analysis of the cerebrospinal fluid proteome identifies molecular signatures of frontotemporal lobar degenerationRowan Saloner, Adam M Staffaroni, Eric B Dammer, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 1, 2019
Clinical and volumetric changes with increasing functional impairment in familial frontotemporal lobar degenerationNicholas T Olney, Elise Ong, Sheng-Yang M Goh, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 6, 2019
Individualized atrophy scores predict dementia onset in familial frontotemporal lobar degenerationAdam M Staffaroni, Yann Cobigo, Sheng-Yang M Goh, et al.
Annals of Neurology|January 29, 2026
Individualized Atrophy-Based Prediction of Dementia Progression in Familial Frontotemporal Lobar Degeneration With Bayesian Linear Mixed-Effects ModelingShubir Dutt, Dana Leichter, Yann Cobigo, et al.
Neurology|April 8, 2021
Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar DegenerationJulio C Rojas, Ping Wang, Adam M Staffaroni, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|January 9, 2020
Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIH-EXAMINER as a potential clinical trial endpointAdam M Staffaroni, Lynn Bajorek, Kaitlin B Casaletto, et al.
JAMA|September 14, 2021
Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial, Michael A Schwarzschild, Alberto Ascherio, et al.
Nature Medicine|September 22, 2022
Temporal order of clinical and biomarker changes in familial frontotemporal dementiaAdam M Staffaroni, Melanie Quintana, Barbara Wendelberger, et al.
Neuron|May 3, 2024
Genome sequence analyses identify novel risk loci for multiple system atrophyRuth Chia, Anindita Ray, Zalak Shah, et al.
JAMA Neurology|March 26, 2014
A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit, M Flint Beal, David Oakes, et al.
Pageof 34

Showing results (321-330 of 331) with videos related to

Sort By:
Pageof 34
Nature Aging|May 16, 2025
Large-scale network analysis of the cerebrospinal fluid proteome identifies molecular signatures of frontotemporal lobar degenerationRowan Saloner, Adam M Staffaroni, Eric B Dammer, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 1, 2019
Clinical and volumetric changes with increasing functional impairment in familial frontotemporal lobar degenerationNicholas T Olney, Elise Ong, Sheng-Yang M Goh, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 6, 2019
Individualized atrophy scores predict dementia onset in familial frontotemporal lobar degenerationAdam M Staffaroni, Yann Cobigo, Sheng-Yang M Goh, et al.
Annals of Neurology|January 29, 2026
Individualized Atrophy-Based Prediction of Dementia Progression in Familial Frontotemporal Lobar Degeneration With Bayesian Linear Mixed-Effects ModelingShubir Dutt, Dana Leichter, Yann Cobigo, et al.
Neurology|April 8, 2021
Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar DegenerationJulio C Rojas, Ping Wang, Adam M Staffaroni, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|January 9, 2020
Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIH-EXAMINER as a potential clinical trial endpointAdam M Staffaroni, Lynn Bajorek, Kaitlin B Casaletto, et al.
JAMA|September 14, 2021
Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial, Michael A Schwarzschild, Alberto Ascherio, et al.
Nature Medicine|September 22, 2022
Temporal order of clinical and biomarker changes in familial frontotemporal dementiaAdam M Staffaroni, Melanie Quintana, Barbara Wendelberger, et al.
Neuron|May 3, 2024
Genome sequence analyses identify novel risk loci for multiple system atrophyRuth Chia, Anindita Ray, Zalak Shah, et al.
JAMA Neurology|March 26, 2014
A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit, M Flint Beal, David Oakes, et al.
Pageof 34